These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 9893155

  • 1. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
    Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E.
    Proc Assoc Am Physicians; 1999; 111(1):35-44. PubMed ID: 9893155
    [Abstract] [Full Text] [Related]

  • 2. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M, oral cladribine for early MS (ORACLE MS) Study Group.
    Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
    [Abstract] [Full Text] [Related]

  • 3. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.
    Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, Grieb P.
    Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The treatment of chronic progressive multiple sclerosis with cladribine.
    Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J.
    Proc Natl Acad Sci U S A; 1996 Feb 20; 93(4):1716-20. PubMed ID: 8643695
    [Abstract] [Full Text] [Related]

  • 9. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr 20; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 10. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
    Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ.
    J Neurol; 2013 Apr 20; 260(4):1136-46. PubMed ID: 23263473
    [Abstract] [Full Text] [Related]

  • 11. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.
    Rice GP, Filippi M, Comi G.
    Neurology; 2000 Mar 14; 54(5):1145-55. PubMed ID: 10720289
    [Abstract] [Full Text] [Related]

  • 12. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr 14; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.
    Mult Scler; 2019 May 14; 25(6):819-827. PubMed ID: 29716436
    [Abstract] [Full Text] [Related]

  • 16. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A.
    Mult Scler; 2022 Jan 14; 28(1):111-120. PubMed ID: 33969750
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Jan 14; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 18. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):15-27. PubMed ID: 22017519
    [Abstract] [Full Text] [Related]

  • 19. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB, Latimer NR, Damian D, Hettle R, Harty GT, Wong SL.
    Value Health; 2019 Jul 01; 22(7):772-776. PubMed ID: 31277823
    [Abstract] [Full Text] [Related]

  • 20. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 01; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.